Results 51 to 60 of about 137,029 (384)
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
, 2022 Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
Infliximab and anti-infliximab antibody levels in Crohn's disease [PDF]
Frontline Gastroenterology, 2014 ▸ Steenholdt C, Brynskov J, Thomsen OO, et al . Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014;63:919–27. This study, the first controlled trial comparing dose escalation of infliximab with a treatment algorithm ...
openaire +3 more sources
Gastroenterology, 2018 BACKGROUND & AIMS A combination of infliximab and immunomodulators is the most efficacious treatment for Crohn's disease (CD). Patients have the best outcomes when their serum concentrations of these drugs are above a determined therapeutic threshold. We
G. D'Haens +25 more
semanticscholar +1 more source
Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]
, 2017 INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K. +2 more
core +2 more sources
Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease
Pharmaceuticals, 2013 Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn’s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns.
George Alex +3 more
doaj +1 more source
Forced Degradation Testing as Complementary Tool for Biosimilarity Assessment [PDF]
, 2019 Oxidation of monoclonal antibodies (mAbs) can impact their efficacy and may therefore represent critical quality attributes (CQA) that require evaluation.
Dyck, Yan Felix Karl +6 more
core +1 more source
Infliximab and nephrotic syndrome [PDF]
Nephrology Dialysis Transplantation, 2005 Infliximab is a chimeric tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody, which has been used extensively in patients with rheumatoid arthritis and inflammatory bowel disease. It also appears to be effective in other conditions such as psoriasis and ankylosing spondylitis. The major side effect of infliximab is infection.
George Chin, Grant Luxton, Jennet Harvey
openaire +3 more sources
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
New England Journal of Medicine, 2001 BACKGROUND Infliximab is a humanized antibody against tumor necrosis factor alpha (TNF-alpha) that is used in the treatment of Crohn's disease and rheumatoid arthritis. Approximately 147,000 patients throughout the world have received infliximab.
J. Keane +7 more
semanticscholar +1 more source
JAMA psychiatry, 2019 Importance To our knowledge, no study has previously evaluated whether individuals with bipolar depression enriched a priori on the basis of biochemical and/or phenotypic immuno-inflammatory activation would differentially respond to an anti-inflammatory
R. McIntyre +15 more
semanticscholar +1 more source
Heliyon, 2023 Infliximab and its anti-drug antibody (ADA) serum concentrations exhibit a strong correlation with clinical response and loss of response. The use of therapeutic drug monitoring to measure the concentration of infliximab and ADA can facilitate clinical ...
Dong Xiang +7 more
doaj